J-GLOBAL ID：201801007147906954
Update date: Aug. 28, 2024
Ko Sato
Ko Sato
Research field (1)：
Tumor biology
Research theme for competitive and other funds (2)：
2015 - 2018 The effect of oestrogen with BRCA1 dysfunction on carcinogenesis
2011 - 2013 Drug sensitivity of PLK1-overexpressing cancer
Papers (19)：
Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stefanus Lie, Diana G Z Lim, Brendan N K Pang, Sherlly Lim, Joe P S Yeong, et al. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO molecular medicine. 2021. e13366
Teppei Iwata, Anna S Sedukhina, Manabu Kubota, Shigeko Oonuma, Ichiro Maeda, Miki Yoshiike, Wataru Usuba, Kimino Minagawa, Eleina Hames, Rei Meguro, et al. A new bioinformatics approach identifies overexpression of GRB2 as a poor prognostic biomarker for prostate cancer. Scientific reports. 2021. 11. 1. 5696-5696
Keiko Oda-Kawashima, Anna S Sedukhina, Naoki Okamoto, Mariya Lytvyn, Kimino Minagawa, Teppei Iwata, Toshio Kumai, Eri Sato, Eiichi Inada, Ayako Yamaura, et al. NF-kB signaling in cardiomyocytes is inhibited by sevoflurane and promoted by propofol. FEBS open bio. 2020
Anna Sedukhina, Ko Sato. Multistep in silico analysis for precision oncology in triple negative breast cancer. CANCER SCIENCE. 2018. 109. 452-452
Ko Sato. Two kills with one shot: A biomarker with therapeutic implications in poor prognosis gastric cancers. CANCER RESEARCH. 2017. 77. 22
